844-MY NK CELLScontact@nantkwest.com

      INVESTOR RELATIONS

      2014 News

      Keyword Search
       
      2017 | 2016 | 2015 | 2014
      DateTitle 
      12/29/14Conkwest Appoints Robert Rosen and Henry Ji to its Board of Directors
      SAN DIEGO (December 29, 2014) – Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast®, a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D. to the Company’s Board of Directors. Mr. Rosen is President of Heron Therapeutics (NASDAQ: HRTX) and Dr. Ji is co-founder, President and CEO of Sorrento Therapeutics, Inc. (NASDAQ: SRNE).“Robert Rosen and Henry Ji bring valuable ski... 
      Printer Friendly Version
      12/24/14Conkwest Announces $50M in Strategic Investments and Appoints Nantworks Founder, Dr. Patrick Soon-Shiong as Co-Chairman of the Board
      SAN DIEGO (December 24, 2014) —Conkwest, Inc., the Natural Killer Cell Company of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast® as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and biotechnology entrepreneur, has entered into a definitive agreement to purchase approximately $48 million of the Company’s Class A Common Stock. In connection with the investment, he will be named Co-Chairman of... 
      Printer Friendly Version
      12/19/14Sorrento and Conkwest Announce Exclusive Global Collaboration Developing Next Generation Cancer Immunotherapy with “Off-the-Shelf” Chimeric Antigen Receptor–Tumor Attacking Natural Killer (CAR-taNK™) Cell Lines
      San Diego and Cardiff-by-the-Sea, CA (Dec. 19, 2014) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast®, a Natural Killer (NK) cell-line based therapy, announced today that the companies have entered into a definitive agreement to jointly develop next generation CAR-taNK™ (pronounced as “Car-Tank”) immunotherapies for ... 
      Printer Friendly Version